Introduction
============

The morbidity and mortality rates of lung cancer rank first in malignant tumors, among which non-small cell lung cancer (NSCLC) occupies a major position in lung cancer, so finding treatment for NSCLC is extremely urgent ([@b1-ol-0-0-8938]). At present, the treatment of NSCLC has been developed from traditional comprehensive treatment, such as surgery and chemotherapy, to individualized treatment. However, the cure rate is not high and NSCLC cannot be radically cured, so better treatment means and methods are still needed ([@b2-ol-0-0-8938],[@b3-ol-0-0-8938]). A large number of studies have shown that the poor prognosis of patients with NSCLC may be related to a low response rate to chemotherapy or primary/secondary drug resistance produced during the process of combined chemotherapy ([@b4-ol-0-0-8938]). With the deepening of research on related genes to the prediction of curative effect of chemotherapeutic and targeted drugs, the development and application of individualized chemotherapy and individualized targeted therapy for NSCLC have been greatly promoted ([@b5-ol-0-0-8938]). Genes, such as epithelial growth factor receptor (*EGFR*), breast cancer 1 (*BRCA1*) and receptor-associated protein 80 (*RAP80*), are all effective genes in the treatment of NSCLC. The combined detection of several genes that can predict the curative effect can provide an important reference basis for the development of NSCLC treatment programs ([@b6-ol-0-0-8938]). In the present study, expression of *BRCA1* and *RAP80* and *EGFR* gene mutations in 51 NSCLC patients were detected, and their association were analyzed, so as to understand the association of *EGFR* gene mutations with expression of BRCA1 and RAP80 in NSCLC patients, and provide a basis for further exploring more effective individualized treatment programs for NSCLC patients.

Materials and methods
=====================

Patients
--------

### General data

In the present study, 51 NSCLC patients admitted and treated in the Thoracic Surgery Department of The Affiliated Jiangyin Hospital of Southeast University Medical College (WuXi, China) and who underwent biopsy or surgery from September 2014 to September 2016 were selected, and general data and smoking status were recorded. The study was approved by the Ethics Committee of The Affiliated Jiangyin Hospital of Southeast University Medical College and informed consents were signed by the patients or guardians.

### Main reagents

EGFR primer was provided by Guangzhou RiboBio Co., Ltd. (Guangzhou, China). Polymerase chain reaction (PCR) primers for BRCA1 and RAP80 were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). Tissue protein extraction kits were purchased from Nanjing KeyGen Biotech Development Co., Ltd. (Nanjing, China). RNAiso Plus, PrimeScript^®^ RT reagent kit with gDNA Eraser and SYBR^®^Premix Ex Taq™ II (Tli RNaseH Plus) were purchased from Takara Biotechnology Co., Ltd. (Dalian, China). TRIzol total RNA extraction kits were from Tiangen Biotech Co., Ltd. (Beijing, China). Reverse transcription-polymerase chain reaction (RT-PCR) kits were from Tiangen Biotech Co., Ltd. Bicinchoninic acid (BCA) protein quantification kits and BeyoECL Plus kits were from Beyotime Institute of Biotechnology (Haimen, China). Rabbit anti-human glyceraldehyde-3-phosphate dehydrogenase (cat. no. 2118; 1:800), BRCA1 (cat. no. 14823; 1:800) and RAP80 (cat. no. 14466; 1:800) monoclonalantibodies, goat anti-rabbit HRP (cat. no. 7074; 1:1,000) and fluorescence secondary polyclonal antibodies (cat. no. 4412; 1:100), all were purchaced from Cell Signaling Technology Europe (B.V., Leiden, The Netherlands).

Experimental methods
--------------------

### Hematoxylin and eosin (H&E) histopathological staining

Tissues in control and NSCLC group were dehydrated, embedded in paraffin, and cut into 5 µm slices for section making and staining. After H&E staining and sealing, sections in control and NSCLC group were observed under an upright microscope (Olympus, Tokyo, Japan) for pathological differences of tissue sections in the two groups, followed by photography and analysis.

### Immunofluorescence staining

The paraffin sections of lung tissues in control and NSCLC group were dewaxed via xylene and dehydrated with gradient alcohol, followed by antigen retrieval. Then sections were washed with 0.01 M phosphate buffered saline (PBS) (pH 7.4) 3 times (5 min each time), sealed in a wet box containing 10% bull serum albumin at 37°C for 30 min. Sections were added dropwise with the fluorescence-labeled antibody appropriately diluted at 1:100, placed in the wet box and incubated at 4°C overnight. After being washed with PBS (pH 7.4) 3 times (5 min each time), sections were added dropwise with the fluorescence-labeled secondary antibody (diluted at 1:100) in the dark, and incubated in a wet box at 37°C for another 2 h. Finally, sections were sealed with buffered glycerol, observed and photographed under an upright fluorescence microscope (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### RT-PCR

An appropriate number of lung tissues in control and NSCLC group were rapidly transferred into 1 ml TRIzol reagent, fully ground and homogenized, let stand at room temperature for 5 min and lysed completely, and centrifuged at 12,000 × g and 4°C for 5 min. Then the supernatant was carefully taken and added with chloroform. The mixture was mixed evenly, let stand at room temperature for 5 min, and centrifuged at 12,000 × g at 4°C for 15 min. The supernatant was carefully taken, added with the same volume of isopropanol, let stand at room temperature for 10 min, and centrifuged at 12,000 × g at 4°C for 10 min. The sediment was retained, added with 75% ethanol and mixed evenly. Finally, RNase-free water was added to completely dissolve the sediment. Then optical density (OD)260/OD280 ratio and the RNA concentration were measured. Stepwise amplification was performed according to the instructions and primer sequence templates shown in [Table I](#tI-ol-0-0-8938){ref-type="table"}, and the reaction products were subjected to RT-PCR analysis.

### Western blot analysis

Lung tissues from the control and NSCLC group were washed twice with ice normal saline, respectively. According to instructions of the total protein extraction kit, tissues were added with lysis buffer homogenized using a tissue homogenizer for 1 min and centrifuged, and the supernatant was collected. The concentration of protein was measured using the BCA protein concentration assay kit. Total protein extracting solution and 2X loading buffer were mixed evenly at a volume ratio of 1:1, treated with boiling water bath for 5 min and naturally cooled. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separation gel in an appropriate proportion was prepared according to the molecular weight of target protein, and frozen for about 1 h. Then 5% SDS-PAGE concentration gel was prepared and frozen for about 30 min. Electrophoretic buffer solution and denatured protein samples were added into the loading wells for loading based on the protein concentration, and the total protein content in each well was kept the same. The electrophoresis was performed under constant pressure of 220 V until the bromophenol blue reached the bottom of the gel. According to the molecular weight of target protein, the gel was cut and placed into transfer buffer. A layer of polyvinylidene fluoride (PVDF) membrane and six layers of filter paper were cut according to the size of the gel. PVDF membrane was immersed into the methanol for 10 sec, and PVDF membrane and filter paper were placed into the transfer buffer. Then the positive pole - three layers of filter paper - PVDF membrane - gel - three layers of filter paper - negative pole were placed on the membrane transfer instrument in this order. Their edges were aligned to prevent blistering. After the membrane transfer under constant pressure of 110 V for 2 h, the membrane attached with protein was sealed using 5% skim milk powder at room temperature for 2 h. The sealed membrane was washed with Tris-buffered saline with Tween-20 (TTBS) for 5 min, and incubated in the primary antibody in corresponding proportion at 4°C overnight. After the membrane was washed with TTBS for 5 min (10 min each time), it was incubated using the corresponding secondary antibody on a shaking table at room temperature for 3 h, and it was washed again with TTBS 3 times (10 min each time). After the gel imager was warmed up for 30 min, reagent A and B in electrochemiluminescence (ECL) kit were evenly mixed at a volume ratio of 1:1, added dropwise onto the PVDF membrane, followed by color development in the dark for 1 min. Excess liquid around the membrane was sucked dry with the filter paper and the membrane was placed into the gel imager, followed by photography under the dynamic integral mode and observation of results. Image analysis software (V3 Western Workflow™; Bio-Rad Laboratories, Inc.) was used to analyze the images.

### EGFR gene detection

Blood specimens of NSCLC patients were collected to extract gDNA and detect *EGFR* gene in peripheral leucocytes. Peripheral venous blood was extracted from the participants of the study to extract DNA. *EGFR* gene was detected via PCR and gel electrophoresis. The forward primer and reverse primer of EGFR gene are as follows: 5′-CTTCGGGGAGCAGCGATGCGAC-3′ (forward) and 5′-ACCAATACCTATTCCGTTACAC-3′ (reverse).

### Statistical analysis

Experimental data are presented as mean ± standard deviation (mean ± SD), and SSPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for the statistical analysis of experimental results. Data were analyzed using analysis of variance or t-test and the post-hoc test was Dunnett\'s test. P\<0.05 was considered to indicate a statistically significant analysis.

Results
=======

### General data of patients

The general conditions of NSCLC patients were recorded, and statistical results are shown in [Table II](#tII-ol-0-0-8938){ref-type="table"} relating to sex, age, history, stage and grade of 51 NSCLC patients.

### Smoking status of patients

The smoking status of NSCLC patients was recorded. As shown in [Table III](#tIII-ol-0-0-8938){ref-type="table"}, NSCLC patients with a smoking history accounted for 64.71%, those who smoked for more than 20 years accounted for 81.82%, and those who had quit smoking accounted for 78.13%, suggesting that NSCLC has a certain association with smoking.

### H&E staining results

H&E staining showed that there were significant pathological differences in lung tissues between control and NSCLC group. Compared with those in control group, the structure of lung tissue was destroyed, nuclear chromatin became darker, and a large number of cancer cells were produced in NSCLC group ([Fig. 1](#f1-ol-0-0-8938){ref-type="fig"}).

### Immunofluorescence staining results

The expression of BRCA1 and RAP80 in lung tissues in control and NSCLC group were detected via immunofluorescence method. Compared with those in control, the expression of BRCA1 and RAP80 in NSCLC group were significantly decreased, indicating that BRCA1 and RAP80 are involved in the occurrence and development of NSCLC ([Fig. 2](#f2-ol-0-0-8938){ref-type="fig"}).

### RT-PCR results of BRCA1 and RAP80 mRNA

The total RNA was extracted from lung tissue samples in control and NSCLC group, respectively. Results of RT-PCR revealed that BRCA1 and RAP80 mRNA in NSCLC were significantly increased compared with those in control group ([Fig. 3](#f3-ol-0-0-8938){ref-type="fig"}).

### Western blot results of BRCA1 and RAP80 proteins

The protein was extracted from lung tissue samples in control and NSCLC group, respectively. Results of western blot showed that the BRCA1 and RAP80 protein expressions in NSCLC were obviously increased compared with those in control group ([Fig. 4](#f4-ol-0-0-8938){ref-type="fig"}).

### EGFR gene mutations

*EGFR* gene mutations were detected in 14 out of 51 NSCLC patients, including 1 case of Exon20: s768I, 1 case of Exon 21: L861Q, 1 case of L858R, 1 case of DEL19, 1 case of L858R, 1 case of EXON 20 Q787Q, 1 case of EXON 21, 4 cases of DEL19, and 5 cases of wild-type ([Table IV](#tIV-ol-0-0-8938){ref-type="table"}).

Discussion
==========

NSCLC, a common malignant tumor, seriously threatens human health ([@b7-ol-0-0-8938]). According to large data in China, the incidence rate of NSCLC in men ranks first in malignant tumors, while that in women is second only to that of breast cancer ([@b8-ol-0-0-8938]). With the development of economy and science and technology, the treatment of NSCLC has entered the stage of individualized treatment. In particular, research and development of drugs targeting EGFR, BRCA1 and RAP80 have milestone significance in the diagnosis and treatment of NSCLC ([@b9-ol-0-0-8938]--[@b11-ol-0-0-8938]).

EGFR is an expression product of proto-oncogene c-erbB1, a member of the human epidermal receptor family ([@b12-ol-0-0-8938]). *EGFR* gene plays an important role in many physiological processes, including cell growth, proliferation and differentiation. Abnormalities in the *EGFR* gene will lead to a variety of diseases, such as cancer, diabetes mellitus, immunodeficiency and cardiovascular diseases ([@b13-ol-0-0-8938]). *BRCA1* is a gene discovered in 1990, which is directly related to hereditary breast cancer. *BRCA1* is a gene that inhibits the occurrence of malignant tumors, which plays an important role in regulating the replication of human cells, genetic material DNA damage repair and normal growth of cells ([@b14-ol-0-0-8938]--[@b17-ol-0-0-8938]). Moreover, RAP80 also plays a critical role in DNA damage response, which can promote a series of repair proteins to be located to the correct DNA damage site ([@b18-ol-0-0-8938]--[@b20-ol-0-0-8938]). In conclusion, *EGFR, BRCA1* and *RAP80* play key roles in the occurrence and development of tumors, and they may be target genes for tumor treatment.

In the present study, 51 NSCLC patients admitted and treated in the Thoracic Surgery Department of the hospital and who underwent biopsy or surgery from September 2014 to September 2016 were selected, and general data and smoking status were recorded. It was found that NSCLC had a association with smoking. H&E histopathological staining method was used to detect pathological differences in lung tissues between control and NSCLC group. H&E histopathological staining showed that the structure of lung tissues was destroyed, nuclear chromatin became darker and a large number of cancer cells were produced in NSCLC compared with those in control group. Immunofluorescent staining method was used to detect the fluorescence expression of BRCA1 and RAP80 proteins in both groups, and results revealed that the expression of fluorescence of BRCA1 and RAP80 proteins in NSCLC group was significantly increased. RT-PCR and western blot proved that the BRCA1 and RAP80 mRNA and protein expression in NSCLC group were significantly increased. Besides, *EGFR* gene mutations were detected in 14 out of 51 patients. In summary, NSCLC has a association with smoking, expression of BRCA1 and RAP80 is closely related to the occurrence and development processes of NSCLC, and EGFR mutation is also significantly associated with NSCLC. It is expected that the key roles of EGFR, BRCA1 and RAP80 in NSCLC in further research will clarify that they can be the targets of prevention, diagnosis and treatment of this disease.
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![BRCA1 and RAP80 protein expression in lung tissues in control group and NSCLC group. Compared with control group, \*\*P\<0.05. BRCA1, breast cancer 1; RAP80, receptor-associated protein 80; NSCLC, non-small cell lung cancer.](ol-16-02-2201-g03){#f4-ol-0-0-8938}

###### 

RT-PCR primer sequences of BRCA1, RAP80 and β-actin mRNA.

  Gene name   Primer sequence
  ----------- ------------------------------------
  *BRCA1*     F: 5′-ACAGCTGTGTGGTGCTTCT-GTG-3′
              R: 3′-CATTGTCCTCTGTCCAGGCATC-5′
  *RAP80*     F: 5′-ACATCAAGTCTTCAGAAACAGGAGC-3′
              R: 3′-TGCAGCCTGCCTCTTFCCAT-5′
  β-*actin*   F: 5′-GAGCCGGGAAATCGTGCGT-3′
              R: 3′-GGAAGGAAGGCTGGAAGATG-5′

RT-PCR, reverse transcription-polymerase chain reaction; BRCA1, breast cancer 1; RAP80, receptor-associated protein; mRNA, messanger RNA.

###### 

General data of patients.

  Groups      No.   (%)
  ----------- ----- -------
  Sex               
    Male      37    72.55
    Female    14    27.45
  Age               
    \<60      30    58.82
    ≥60       21    41.18
  History           
    Adeno     36    70.59
    SCC       15    29.41
  Stage             
    IIIA      3     5.88
    IIIB      12    23.53
    IV        36    70.59
  Grade             
    G1        2     3.92
    G1--2     3     5.88
    G2        8     15.69
    G2-3      3     5.88
    G3        12    23.53
    Unknown   23    45.10

###### 

Smoking status of patients.

  Groups              No.   (%)
  ------------------- ----- -------
  Smoking history           
    Yes               33    64.71
    No                18    35.29
  Smoking pack-year         
    \<20              5     15.15
    ≥20               27    81.82
    Unknown           1     3.03
  Quit smoking              
    Yes               25    78.13
    No                1     3.13
    Unknown           6     18.75

###### 

*EGFR* gene mutations.

  Type                             Νo.   (%)
  -------------------------------- ----- -------
  Wild-type                        5     35.72
  Exon 20: s768I; Exon 21: L861Q   1     7.14
  L858R                            1     7.14
  Del19                            4     28.58
  Del19, L858R                     1     7.14
  Exon 20 Q787Q                    1     7.14
  Exon 21                          1     7.14

[^1]: Contributed equally
